Vitamin D3 analogs (VD3A), such as calcipotriol (calcipotriene), calcitriol, tacalcitol, and maxacalcitol, are a first-line treatment for psoriasis because they are known to modulate the vitamin D receptor (VDR)-mediated responses, thereby promoting cell differentiation, inhibiting proliferation, enhancing apoptotic processes, and exerting immunomodulatory activity [279,280]. Here, VDR is linked to psoriasis.